Bacil Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2026 ,inter alia, to consider and approve 1. Approval of unaudited Financial ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bacil Pharma Ltd has informed BSE that its Board of Directors will meet on Friday, 13 February 2026. The main agenda item is the approval of the unaudited financial results for the quarter ended 31 December 2025 (Q3 FY26). The notice also includes a standard agenda item allowing any other business with the Chairperson's permission. The intimation is filed under SEBI Listing Regulations, 2015, and signed by Director & CFO Ms. Chaitali Kalpataru Shah. No financial figures or operational details have been disclosed in this filing — it is a routine pre-results announcement.
This is a standard regulatory intimation with no direct impact on shareholders. Investors should watch for the actual Q3 FY26 results, which will be disclosed after the board meeting on 13 February 2026, for insights into the company's quarterly performance.